Free Webinar Explores Safe Scaling of Pressure Reactions
News May 24, 2013
Mettler Toledo has presented the next installment in its thought-leading, on-demand webinar series. Entitled “Characterize, Optimize and Scale-up Pressure Reactions - Challenges and Solutions” and presented by Mettler Toledo Market Manager Brian Wittkamp, PhD, the free presentation reviews critical pressure-reaction design parameters.
It also explores enabling technologies such as Fourier Transform Infrared technology (FTIR) that help chemists gain better reaction control and more valuable reaction information for easier, safer and more cost-effective scale-up.
Although the objectives of chemical development have not changed in recent years, Dr. Wittkamp notes that the market has.
Chemists must bring new products to market faster, necessitating quick identification of workable opportunities and even quicker rejection of untenable ones.
FTIR instruments (ReactIR) helps deliver a process that is safe, economically viable and robust by providing critical understanding at small scale where lab resources, including development time, can be limited.
The data collected then allows these findings to be applied at larger scales.
Using a Mettler Toledo Easy Max synthesis workstation combined with Mettler Toledo ReactIR technology, two pressurized hydrogenation reactions are analyzed.
In the first, a one-step hydrogenation of a substitute 2-cyclohexene-1-one, mix rates are shown to influence reaction times. In the second, a complex hydrogenation of substituted hydrobenzene, accumulation of unstable hydroxylamine intermediate is prevented.
In each case, in situ FTIR data provides higher-value reaction chemistry information when compared with potentially time-consuming and error-prone offline sampling techniques.
Precise FTIR monitoring of critical parameters is shown to enhance researchers’ understanding and enable faster, safer optimization.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018